Study Evaluates Patients With Kidney Disease After Undergoing TAVR By Cardiac Interventions Today October 16, 2017—The American College of Cardiology (ACC) announced the publication of a study demonstrating a relatively low rate of patients with chronic kidney disease undergoing transcatheter […]
Tag: TAVR
New Study Shows That Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality Associated with Transcatheter Aortic Valve Replacement (TAVR)
SANTA ROSA, Calif.–(BUSINESS WIRE)–Claret Medical® today announced publication of a new study in the Journal of the American College of Cardiology (JACC): Cardiovascular Interventions that underscores the role of the Sentinel Cerebral Protection System (CPS) in significantly reducing the early occurrence of […]
Protembis Announces Successful First-in-Human Use of Its ProtEmbo® Cerebral Protection System in European Trial
AACHEN, Germany–(BUSINESS WIRE)–Protembis GmbH, a privately held medical device company, announced today the first clinical applications of its ProtEmbo® Cerebral Protection System to complement a transcatheter aortic valve replacement (TAVR) procedure. The ProtEmbo® System is an intra-aortic filter device that deflects embolic […]
InspireMD’s Cguard Carotid Embolic Prevention System Featured At The SOLACI CACI Congress Of Cardiology 2017 In Buenos Aires
TEL AVIV, ISRAEL–(Marketwired – August 03, 2017) – InspireMD, Inc. (NYSE MKT: NSPR) (NYSE MKT: NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that an endovascular interventional procedure featuring the CGuard™ […]
Medtronic Expands TAVR Access to More Patients With Symptomatic, Severe Aortic Stenosis Upon Intermediate Risk FDA Approval
Press Release DUBLIN – July 10, 2017 – Medtronic plc (NYSE: MDT) today announced the expanded U.S. Food and Drug Administration (FDA) approval of the self-expanding CoreValve(TM) Evolut(TM) transcatheter aortic valve replacement (TAVR) platform to include patients with symptomatic severe aortic […]
Innovative Cardiovascular Solutions Raises $5.0 Million in Series B Financing for Advanced Device Development and Initiation of U.S. Clinical Activities
KALAMAZOO, Mich., July 11, 2017 /PRNewswire/ — Innovative Cardiovascular Solutions, LLC (ICS), a privately-held clinical stage company headquartered in Kalamazoo, MI, announced today completion of an oversubscribed Series B round of financing totaling $5M USD. The company is currently developing the EMBLOK™ Embolic Protection System […]
Medtronic Expands TAVR Access to More Patients With Symptomatic, Severe Aortic Stenosis Upon Intermediate Risk FDA Approval
DUBLIN – July 10, 2017 – Medtronic plc (NYSE: MDT) today announced the expanded U.S. Food and Drug Administration (FDA) approval of the self-expanding CoreValve(TM) Evolut(TM) transcatheter aortic valve replacement (TAVR) platform to include patients with symptomatic severe aortic stenosis who […]
Edwards Lifesciences (EW)’ Novel Self-Expanding Transcatheter Heart Valve Demonstrates Excellent Early Patient Outcomes
PARIS, May 17, 2017 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced late-breaking data at EuroPCR 2017 demonstrating excellent clinical outcomes for transcatheter aortic valve replacement […]
Venus Medtech’s TAVR Device Is Approved By CFDA, Creating A New Era Of Interventional Cardiology In China
HANGZHOU, China, April 28, 2017 /PRNewswire/ — Venus Medtech (Hangzhou) Inc., announced on April 25th that its transcatheter aortic valve system – Venus A-valve – has been approved by China Food and Drug Administration(“CFDA”) (registration no.: 20173460680) for sale in China. […]
Boston Scientific agrees to acquire Symetis
MARLBOROUGH, Mass., March 30, 2017 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced a definitive agreement to acquire Symetis SA, a privately-held Swiss structural heart company focused on minimally-invasive transcatheter aortic valve implantation (TAVI) devices, for $435 million in up-front cash. The […]